Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viking Therapeutics (VKTX) Other Non-Current Liabilities (2017)

Viking Therapeutics (VKTX) has disclosed Other Non-Current Liabilities for 3 consecutive years, with $47113.0 as the latest value for Q1 2017.

  • Quarterly Other Non-Current Liabilities fell 76.78% to $47113.0 in Q1 2017 from the year-ago period, while the trailing twelve-month figure was $47113.0 through Mar 2017, down 76.78% year-over-year, with the annual reading at $183611.0 for FY2015, N/A changed from the prior year.
  • Other Non-Current Liabilities hit $47113.0 in Q1 2017 for Viking Therapeutics, down from $202882.0 in the prior quarter.
  • In the past five years, Other Non-Current Liabilities ranged from a high of $202882.0 in Q1 2016 to a low of $47113.0 in Q1 2017.
  • Historically, Other Non-Current Liabilities has averaged $144535.3 across 3 years, with a median of $183611.0 in 2015.
  • Biggest YoY gain for Other Non-Current Liabilities was 76.78% in 2017; the steepest drop was 76.78% in 2017.
  • Year by year, Other Non-Current Liabilities stood at $183611.0 in 2015, then rose by 10.5% to $202882.0 in 2016, then tumbled by 76.78% to $47113.0 in 2017.
  • Business Quant data shows Other Non-Current Liabilities for VKTX at $47113.0 in Q1 2017, $202882.0 in Q1 2016, and $183611.0 in Q4 2015.